Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma DOI Creative Commons

Ruipeng Zheng,

Guoqiang Wang, Zhiqiang Pang

et al.

Cancer Medicine, Journal Year: 2020, Volume and Issue: 9(12), P. 4232 - 4250

Published: April 12, 2020

Abstract Background Gut microbiota (GM) of patients with liver cancer is disordered, and syet no study reported the GM distribution cirrhosis‐induced HCC (LC‐HCC) nonliver (NLC‐HCC). In this study, we aimed to characterize gut dysbiosis LC‐HCC NLC‐HCC elucidate role in pathogenesis HCC. Methods A consecutive series fecal samples hepatitis (24 patients), cirrhosis (75 patients: 35 infected by HBV, 25 HCV, 15 alcoholic disease), healthy controls (20 patients) were obtained sequenced on Illumina Hiseq platform. The group contains 52 23 NLC‐HCC. Bioinformatic analysis intestinal was performed QIIME MicrobiomeAnalyst. Results Alpha‐diversity showed that microbial diversity significantly decreased LC group, there significant differences 3 phyla 27 genera vs other groups (the healthy, hepatitis, groups). Beta‐diversity large between others. increased from Characterizing NLC‐HCC, found rather than Thirteen discovered be associated tumor size Three biomarkers ( Enterococcus , Limnobacter Phyllobacterium ) could used for precision diagnosis. We also HBV infection, HCV or ALD (alcoholic disease) not Conclusion Our results suggest disorders are more common LC‐HCC. butyrate‐producing decreased, while producing‐lipopolysaccharide (LPS) patients. Further studies may achieve early diagnosis new therapeutic approaches

Language: Английский

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis DOI Creative Commons
Kuei‐Chuan Lee, Pei-Shan Wu, Han‐Chieh Lin

et al.

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(1), P. 77 - 98

Published: Oct. 13, 2022

The initial presentation of non-alcoholic steatohepatitis (NASH) is hepatic steatosis. dysfunction lipid metabolism within hepatocytes caused by genetic factors, diet, and insulin resistance causes accumulation. Lipotoxicity, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress would further contribute to hepatocyte injury death, leading inflammation immune in the liver. During healing process, accumulation an excessive amount fibrosis might occur while healing. development NASH liver fibrosis, gut-liver axis, adipose-liver renin-angiotensin system (RAS) may be dysregulated impaired. Translocation bacteria or its end-products entering could activate hepatocytes, Kupffer cells, stellate exacerbating steatosis, inflammation, fibrosis. Bile acids regulate glucose through Farnesoid X receptors intestine. Increased adipose tissue-derived non-esterified fatty aggravate leptin also plays a role fibrogenesis, decreased adiponectin resistance. Moreover, dysregulation peroxisome proliferator-activated liver, adipose, muscle tissues impair metabolism. In addition, RAS acid metabolism, treatment includes lifestyle modification, pharmacological therapy, non-pharmacological therapy. Currently, weight reduction modification surgery most effective However, vitamin E, pioglitazone, obeticholic have been suggested. this review, we will introduce some new clinical trials experimental therapies for related

Language: Английский

Citations

113
d -lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma DOI Creative Commons
Shulan Han, Xueying Bao, Yifang Zou

et al.

Science Advances, Journal Year: 2023, Volume and Issue: 9(29)

Published: July 19, 2023

The polarization of tumor-associated macrophages (TAMs) from M2 to M1 phenotype demonstrates great potential for remodeling the immunosuppressive tumor microenvironment (TME) hepatocellular carcinoma (HCC). d-lactate (DL; a gut microbiome metabolite) acts as an endogenous immunomodulatory agent that enhances Kupffer cells clearance pathogens. In this study, DL transformation TAMs was confirmed, and mechanisms underlying such were mainly due modulation phosphatidylinositol 3-kinase/protein kinase B pathway. A poly(lactide-co-glycolide) nanoparticle (NP) used load DL, DL-loaded NP modified with HCC membrane macrophage-binding peptide (M2pep), forming nanoformulation (DL@NP-M-M2pep). DL@NP-M-M2pep transformed remodeled TME in mice, promoting efficacy anti-CD47 antibody long-term animal survival. These findings reveal TAM modulatory function provide combinatorial strategy immunotherapy.

Language: Английский

Citations

110
Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention DOI Creative Commons
Naomi F. Lange, Pompilia Radu, Jean‐François Dufour

et al.

Journal of Hepatology, Journal Year: 2021, Volume and Issue: 75(5), P. 1217 - 1227

Published: July 31, 2021

In many countries worldwide, the burden of hepatocellular carcinoma (HCC) associated with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) is increasing. Preventive strategies are needed to counteract this trend. review, we provide an overview evidence on preventive in NAFLD-associated HCC. We consider impact lifestyle factors such as weight loss, physical activity, smoking, dietary patterns food items, including coffee alcohol, both HCC NAFLD/NASH. Furthermore, chemopreventive treatments, aspirin, antidiabetic treatments statins summarised. The role adjuvant therapies for tertiary prevention briefly reviewed.

Language: Английский

Citations

105
Hepatocellular Carcinoma in 2021: An Exhaustive Update DOI Open Access
Cyriac Abby Philips, S Rajesh, Dinu Chandran Nair

et al.

Cureus, Journal Year: 2021, Volume and Issue: unknown

Published: Nov. 5, 2021

Primary liver cancer is a challenging global health concern with an estimated more than million persons to be affected annually by the year 2025. The commonest type hepatocellular carcinoma (HCC), which has been increasing in incidence world over, mostly due chronic viral hepatitis B infection. In last decade, paradigm changes etiology, understanding of molecular biology, and pathogenesis, including role gut microbiota; medical surgical treatments, outcome trends are notable. application omics-based technology helped us unlock immune landscape HCC, through novel targets for drug treatment such as immune-checkpoint inhibitors have identified. Novel tools surveillance diagnosis HCC include protein-, genomics-, composite algorithm-based clinical/biomarker panels. Magnetic resonance imaging-based techniques improved ancillary features that enhance classical criteria while positron emission tomography shown value prognostication. Identification microbiota causation progression opened areas therapeutic research. A select group patients still benefit from modified early interventional radiology treatments. Improvements radiotherapy protocols, identification parameters futility among radiological interventions, emergence first-line systemic therapies combination antiangiogenic seen change progression-free overall survival. current review aimed at providing exhaustive updates on biomarker diagnosis, imaging, recommended options HCC.

Language: Английский

Citations

104
Biomarkers for immunotherapy of hepatocellular carcinoma DOI
Tim F. Greten, Augusto Villanueva, Firouzeh Korangy

et al.

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(11), P. 780 - 798

Published: Sept. 19, 2023

Language: Английский

Citations

97
Interactive Relationships between Intestinal Flora and Bile Acids DOI Open Access

Xiaohua Guo,

Edozie Samuel Okpara,

Wanting Hu

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(15), P. 8343 - 8343

Published: July 28, 2022

The digestive tract is replete with complex and diverse microbial communities that are important for the regulation of multiple pathophysiological processes in humans animals, particularly those involved maintenance intestinal homeostasis, immunity, inflammation, tumorigenesis. diversity bile acids a result joint efforts host microflora. There bidirectional relationship between community that, while flora tightly modulates metabolism synthesis acids, acid pool composition affect homeostasis flora. Homeostatic imbalances systems may lead to development variety diseases, such as inflammatory bowel disease (IBD), colorectal cancer (CRC), hepatocellular carcinoma (HCC), type 2 diabetes (T2DM), polycystic ovary syndrome (PCOS). interactions be (in)directly pathogenesis these diseases.

Language: Английский

Citations

95
Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression DOI
Lirong Peng, Banglun Pan, Xiaoxia Zhang

et al.

Cell Biology and Toxicology, Journal Year: 2022, Volume and Issue: 38(6), P. 1159 - 1173

Published: April 19, 2022

Language: Английский

Citations

84
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target DOI Creative Commons

Mengwei Zhang,

Jinkai Liu,

Qiang Xia

et al.

Experimental Hematology and Oncology, Journal Year: 2023, Volume and Issue: 12(1)

Published: Sept. 28, 2023

Immunotherapy has emerged as an effective treatment for various types of cancers. Recent studies have highlighted a significant correlation between the gut microbiome and patients' response to immunotherapy. Several characteristics microbiome, such community structures, taxonomic compositions, molecular functions, been identified crucial biomarkers predicting immunotherapy immune-related adverse events (irAEs). Unlike other -omics, can serve not only but also potential targets enhancing efficacy Approaches modulating include probiotics/prebiotics supplementation, dietary interventions, fecal microbiota transplantation (FMT), antibiotic administration. This review primarily focuses on elucidating role in cancer improving its efficacy. Notably, we explore reasons behind inconsistent findings observed different studies, highlight underlying benefits antibiotics liver

Language: Английский

Citations

50
Role of the microbiota in response to and recovery from cancer therapy DOI
Stephen J. Blake, Yochai Wolf, Ben Boursi

et al.

Nature reviews. Immunology, Journal Year: 2023, Volume and Issue: 24(5), P. 308 - 325

Published: Nov. 6, 2023

Language: Английский

Citations

46
Molecular mechanisms in MASLD/MASH-related HCC DOI
Xiaobo Wang, Liang Zhang, Bingning Dong

et al.

Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 13, 2024

Liver cancer is the third leading cause of cancer-related deaths and ranks as sixth most prevalent type globally. NAFLD or metabolic dysfunction-associated steatotic liver disease, its more severe manifestation, NASH steatohepatitis (MASH), pose a significant global health concern, affecting approximately 20%-25% population. The increased prevalence disease MASH parallel to increasing rates obesity-associated diseases, including 2 diabetes, insulin resistance, fatty diseases. can progress MASH-related HCC (MASH-HCC) in about 2% cases each year, influenced by various factors such genetic mutations, carcinogen exposure, immune microenvironment, microbiome. MASH-HCC exhibits distinct molecular characteristics compared other causes affects both men women equally. management early intermediate-stage typically involves surgery locoregional therapies, while advanced treated with systemic anti-angiogenic therapies checkpoint inhibitors. In this comprehensive review, we consolidate previous research findings also providing current insights into intricate processes underlying development. We delve MASH-HCC-associated variations somatic progression models, multiomics analysis, immunological microenvironmental impacts, discuss targeted/combined overcome evasion biomarkers recognize treatment responders. By furthering our comprehension mechanisms MASH-HCC, goal catalyze advancement potent strategies, ultimately enhanced patient outcomes.

Language: Английский

Citations

43